|
1
|
Hartwig W, Werner J, Jäger D, Debus J and
Büchler MW: Improvement of surgical results for pancreatic cancer.
Lancet Oncol. 14:e476–e485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh P, Srinivasan R and Wig JD: Major
molecular markers in pancreatic ductal adenocarcinoma and their
roles in screening, diagnosis, prognosis, and treatment. Pancreas.
40:644–652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loos M, Giese NA, Kleeff J, Giese T, Gaida
MM, Bergmann F, Laschinger M, W Büchler M and Friess H: Clinical
significance and regulation of the costimulatory molecule B7-H1 in
pancreatic cancer. Cancer Lett. 268:98–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bazhin AV, Shevchenko I, Umansky V, Werner
J and Karakhanova S: Two immune faces of pancreatic adenocarcinoma:
Possible implication for immunotherapy. Cancer Immunol Immunother.
63:59–65. 2014. View Article : Google Scholar
|
|
6
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ryschich E, Nötzel T, Hinz U, Autschbach
F, Ferguson J, Simon I, Weitz J, Fröhlich B, Klar E, Büchler MW, et
al: Control of T-cell-mediated immune response by HLA class I in
human pancreatic carcinoma. Clin Cancer Res. 11:498–504.
2005.PubMed/NCBI
|
|
8
|
Nomi T, Sho M, Akahori T, Hamada K, Kubo
A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al:
Clinical significance and therapeutic potential of the programmed
death-1 ligand/programmed death-1 pathway in human pancreatic
cancer. Clin Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park IH, Kong SY, Ro JY, Kwon Y, Kang JH,
Mo HJ, Jung SY, Lee S, Lee KS, Kang HS, et al: Prognostic
implications of tumor-infiltrating lymphocytes in association with
programmed death ligand 1 expression in early-stage breast cancer.
Clin Breast Cancer. 16:51–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blank C, Gajewski TF and Mackensen A:
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T
cells as a mechanism of immune evasion: Implications for tumor
immunotherapy. Cancer Immunol Immunother. 54:307–314. 2005.
View Article : Google Scholar
|
|
11
|
Chen Y, Sun J, Zhao H, Zhu D, Zhi Q, Song
S, Zhang L, He S, Kuang Y, Zhang Z, et al: The coexpression and
clinical significance of costimulatory molecules B7-H1, B7-H3, and
B7-H4 in human pancreatic cancer. Onco Targets Ther. 7:1465–1472.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wadle A, Kubuschok B, Imig J, Wuellner B,
Wittig C, Zwick C, Mischo A, Waetzig K, Romeike BF, Lindemann W, et
al: Serological immune response to cancer testis antigens in
patients with pancreatic cancer. Int J Cancer. 119:117–125. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmitz-Winnenthal FH, Galindo-Escobedo
LV, Rimoldi D, Geng W, Romero P, Koch M, Weitz J, Krempien R,
Niethammer AG, Beckhove P, et al: Potential target antigens for
immunotherapy in human pancreatic cancer. Cancer Lett. 252:290–298.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gnjatic S, Ritter E, Büchler MW, Giese NA,
Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen YT, et al:
Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad
Sci USA. 107:5088–5093. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tomaino B, Cappello P, Capello M,
Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De
Angelis C, Gaia E, et al: Autoantibody signature in human ductal
pancreatic adenocarcinoma. J Proteome Res. 6:4025–4031. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kubuschok B, Neumann F, Breit R, Sester M,
Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K,
et al: Naturally occurring T-cell response against mutated p21 ras
oncoprotein in pancreatic cancer. Clin Cancer Res. 12:1365–1372.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wenandy L, Sørensen RB, Sengeløv L, Svane
IM, thor Straten P and Andersen MH: The immunogenicity of the
hTERT540-548 peptide in cancer. Clin Cancer Res. 14:4–7. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gjertsen MK, Bakka A, Breivik J, Saeterdal
I, Solheim BG, Søreide O, Thorsby E and Gaudernack G: Vaccination
with mutant ras peptides and induction of T-cell responsiveness in
pancreatic carcinoma patients carrying the corresponding RAS
mutation. Lancet. 346:1399–1400. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wobser M, Keikavoussi P, Kunzmann V,
Weininger M, Andersen MH and Becker JC: Complete remission of liver
metastasis of pancreatic cancer under vaccination with a HLA-A2
restricted peptide derived from the universal tumor antigen
survivin. Cancer Immunol Immunother. 55:1294–1298. 2006. View Article : Google Scholar
|
|
20
|
Yamaguchi K, Enjoji M and Tsuneyoshi M:
Pancreatoduodenal carcinoma: A clinicopathologic study of 304
patients and immunohistochemical observation for CEA and CA19-9. J
Surg Oncol. 47:148–154. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Komoto M, Nakata B, Amano R, Yamada N,
Yashiro M, Ohira M, Wakasa K and Hirakawa K: HER2 overexpression
correlates with survival after curative resection of pancreatic
cancer. Cancer Sci. 100:1243–1247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heller A, Zörnig I, Müller T, Giorgadze K,
Frei C, Giese T, Bergmann F, Schmidt J, Werner J, Buchler MW, et
al: Immunogenicity of SEREX-identified antigens and disease outcome
in pancreatic cancer. Cancer Immunol Immunother. 59:1389–1400.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cappello P, Tomaino B, Chiarle R, Ceruti
P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A,
Milella M, et al: An integrated humoral and cellular response is
elicited in pancreatic cancer by alpha-enolase, a novel pancreatic
ductal adenocarcinoma-associated antigen. Int J Cancer.
125:639–648. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amedei A, Niccolai E, Benagiano M, Della
Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello
P, et al: Ex vivo analysis of pancreatic cancer-infiltrating T
lymphocytes reveals that ENO-specific Tregs accumulate in tumor
tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol
Immunother. 62:1249–1260. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Capello M, Ferri-Borgogno S, Cappello P
and Novelli F: α-Enolase: A promising therapeutic and diagnostic
tumor target. FEBS J. 278:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tomaino B, Cappello P, Capello M,
Fredolini C, Sperduti I, Migliorini P, Salacone P, Novarino A,
Giacobino A, Ciuffreda L, et al: Circulating autoantibodies to
phosphorylated α-enolase are a hallmark of pancreatic cancer. J
Proteome Res. 10:105–112. 2011. View Article : Google Scholar
|
|
27
|
Cappello P, Rolla S, Chiarle R, Principe
M, Cavallo F, Perconti G, Feo S, Giovarelli M and Novelli F:
Vaccination with ENO1 DNA prolongs survival of genetically
engineered mice with pancreatic cancer. Gastroenterology.
144:1098–1106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Monte L, Reni M, Tassi E, Clavenna D,
Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C and Protti MP:
Intratumor T helper type 2 cell infiltrate correlates with
cancer-associated fibroblast thymic stromal lymphopoietin
production and reduced survival in pancreatic cancer. J Exp Med.
208:469–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Linehan DC and Goedegebuure PS:
CD25+ CD4+ regulatory T-cells in cancer.
Immunol Res. 32:155–168. 2005. View Article : Google Scholar
|
|
30
|
Liyanage UK, Moore TT, Joo HG, Tanaka Y,
Herrmann V, Doher ty G, Drebin JA, Strasberg SM, Eberlein TJ,
Goedegebuure PS, et al: Prevalence of regulatory T cells is
increased in peripheral blood and tumor microenvironment of
patients with pancreas or breast adenocarcinoma. J Immunol.
169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bettelli E, Oukka M and Kuchroo VK:
T(H)-17 cells in the circle of immunity and autoimmunity. Nat
Immunol. 8:345–350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kryczek I, Wei S, Zou L, Altuwaijri S,
Szeliga W, Kolls J, Chang A and Zou W: Cutting edge: Th17 and
regulatory T cell dynamics and the regulation by IL-2 in the tumor
microenvironment. J Immunol. 178:6730–6733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma
L, Xue X, Wei G, Liu X and Fang G: The prevalence of Th17 cells in
patients with gastric cancer. Biochem Biophys Res Commun.
374:533–537. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koyama K, Kagamu H, Miura S, Hiura T,
Miyabayashi T, Itoh R, Kuriyama H, Tanaka H, Tanaka J, Yoshizawa H,
et al: Reciprocal CD4+ T-cell balance of effector
CD62Llow CD4+ and CD62LhighCD25+
CD4+ regulatory T cells in small cell lung cancer
reflects disease stage. Clin Cancer Res. 14:6770–6779. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Warshaw AL and Fernández-del Castillo C:
Pancreatic carcinoma. N Engl J Med. 326:455–465. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Amedei A, Della Bella C, Niccolai E,
Stanflin N, Benagiano M, Duranti R, Del Prete G, Murphy TF and
D'Elios MM: Moraxella catarrhalis-specific Th1 cells in BAL fluids
of chronic obstructive pulmonary disease patients. Int J
Immunopathol Pharmacol. 22:979–990. 2009.
|
|
37
|
Amedei A, Niccolai E, Della Bella C,
Cianchi F, Trallori G, Benagiano M, Bencini L, Bernini M, Farsi M,
Moretti R, et al: Characterization of tumor antigen
peptide-specific T cells isolated from the neoplastic tissue of
patients with gastric adenocarcinoma. Cancer Immunol Immunother.
58:1819–1830. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van Dongen JJ, Langerak AW, Brüggemann M,
Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E,
García-Sanz R, et al: Design and standardization of PCR primers and
protocols for detection of clonal immunoglobulin and T-cell
receptor gene recombinations in suspect lymphoproliferations:
Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia.
17:2257–2317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nagorsen D, Scheibenbogen C, Schaller G,
Leigh B, Schmittel A, Letsch A, Thiel E and Keilholz U: Differences
in T-cell immunity toward tumor-associated antigens in colorectal
cancer and breast cancer patients. Int J Cancer. 105:221–225. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lippitz BE: Cytokine patterns in patients
with cancer: A systematic review. Lancet Oncol. 14:e218–e228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Berlin C, Berg EL, Briskin MJ, Andrew DP,
Kilshaw PJ, Holzmann B, Weissman IL, Hamann A and Butcher EC: Alpha
4 beta 7 integrin mediates lymphocyte binding to the mucosal
vascular addressin MAdCAM-1. Cell. 74:185–195. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rott LS, Briskin MJ, Andrew DP, Berg EL
and Butcher EC: A fundamental subdivision of circulating
lymphocytes defined by adhesion to mucosal addressin cell adhesion
molecule-1. Comparison with vascular cell adhesion molecule-1 and
correlation with beta 7 integrins and memory differentiation. J
Immunol. 156:3727–3736. 1996.PubMed/NCBI
|
|
43
|
Brandacher G, Winkler C, Schroecksnadel K,
Margreiter R and Fuchs D: Antitumoral activity of interferon-gamma
involved in impaired immune function in cancer patients. Curr Drug
Metab. 7:599–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zaidi MR and Merlino G: The two faces of
interferon-γ in cancer. Clin Cancer Res. 17:6118–6124. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Neurath MF and Finotto S: The emerging
role of T cell cytokines in non-small cell lung cancer. Cytokine
Growth Factor Rev. 23:315–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hemdan NY: Anti-cancer versus
cancer-promoting effects of the interleukin-17-producing T helper
cells. Immunol Lett. 149:123–133. 2013. View Article : Google Scholar
|
|
47
|
Bidard FC, Huguet F, Louvet C, Mineur L,
Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C,
et al: Circulating tumor cells in locally advanced pancreatic
adenocarcinoma: The ancillary CirCe 07 study to the LAP 07 trial.
Ann Oncol. 24:2057–2061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tjensvoll K, Nordgård O and Smaaland R:
Circulating tumor cells in pancreatic cancer patients: Methods of
detection and clinical implications. Int J Cancer. 134:1–8. 2014.
View Article : Google Scholar
|
|
49
|
Niccolai E, Prisco D, D'Elios MM and
Amedei A: What is recent in pancreatic cancer immunotherapy? BioMed
Res Int. 2013:4923722013. View Article : Google Scholar : PubMed/NCBI
|
